Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward Chesney

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
The British Journal of Psychiatry : the Journal of Mental Science|May 31, 2023
Point of care assay for blood aripiprazole concentrations: development, validation and utilityMatthew Atkins, David Taylor, Ana Catalan, et al.
Addiction (Abingdon, England)|October 11, 2023
Cannabidiol does not attenuate acute delta-9-tetrahydrocannabinol-induced attentional bias in healthy volunteers: A randomised, double-blind, cross-over studyDominic Oliver, Amir Englund, Edward Chesney, et al.
Frontiers in Psychiatry|May 13, 2026
Acceptability of cannabidiol as a treatment for people at clinical high risk for psychosisDominic Oliver, Edward Chesney, Phoebe Wallman, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 15, 2022
Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratiosAmir Englund, Dominic Oliver, Edward Chesney, et al.
Pharmaceutics|January 8, 2025
Novel Lipid Formulation Increases Absorption of Oral Cannabidiol (CBD)Edward Chesney, Ndabezinhle Mazibuko, Dominic Oliver, et al.
Cannabis and Cannabinoid Research|December 9, 2022
Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Plasma Endocannabinoid Levels in Healthy Volunteers: A Randomized Double-Blind Four-Arm Crossover StudyLucy A Chester, Amir Englund, Edward Chesney, et al.
Neuroscience and Biobehavioral Reviews|May 6, 2024
Exploring causal mechanisms of psychosis riskDominic Oliver, Edward Chesney, Alexis E Cullen, et al.
BMJ Mental Health|August 26, 2025
Are reasons for first using cannabis associated with subsequent cannabis consumption (standard THC units) and psychopathology?Edoardo Spinazzola, Hannah Degen, Isabelle Austin-Zimmerman, et al.
Addiction (Abingdon, England)|February 7, 2023
The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double-blind, placebo-controlled, crossover experimentWill Lawn, Katie Trinci, Claire Mokrysz, et al.
Neuroscience and Biobehavioral Reviews|April 10, 2024
Why we need to pursue both universal and targeted prevention to reduce the incidence of affective and psychotic disorders: Systematic review and meta-analysisSebastien Brodeur, Dominic Oliver, Muhammad S Ahmed, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
The British Journal of Psychiatry : the Journal of Mental Science|May 31, 2023
Point of care assay for blood aripiprazole concentrations: development, validation and utilityMatthew Atkins, David Taylor, Ana Catalan, et al.
Addiction (Abingdon, England)|October 11, 2023
Cannabidiol does not attenuate acute delta-9-tetrahydrocannabinol-induced attentional bias in healthy volunteers: A randomised, double-blind, cross-over studyDominic Oliver, Amir Englund, Edward Chesney, et al.
Frontiers in Psychiatry|May 13, 2026
Acceptability of cannabidiol as a treatment for people at clinical high risk for psychosisDominic Oliver, Edward Chesney, Phoebe Wallman, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 15, 2022
Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratiosAmir Englund, Dominic Oliver, Edward Chesney, et al.
Pharmaceutics|January 8, 2025
Novel Lipid Formulation Increases Absorption of Oral Cannabidiol (CBD)Edward Chesney, Ndabezinhle Mazibuko, Dominic Oliver, et al.
Cannabis and Cannabinoid Research|December 9, 2022
Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Plasma Endocannabinoid Levels in Healthy Volunteers: A Randomized Double-Blind Four-Arm Crossover StudyLucy A Chester, Amir Englund, Edward Chesney, et al.
Neuroscience and Biobehavioral Reviews|May 6, 2024
Exploring causal mechanisms of psychosis riskDominic Oliver, Edward Chesney, Alexis E Cullen, et al.
BMJ Mental Health|August 26, 2025
Are reasons for first using cannabis associated with subsequent cannabis consumption (standard THC units) and psychopathology?Edoardo Spinazzola, Hannah Degen, Isabelle Austin-Zimmerman, et al.
Addiction (Abingdon, England)|February 7, 2023
The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double-blind, placebo-controlled, crossover experimentWill Lawn, Katie Trinci, Claire Mokrysz, et al.
Neuroscience and Biobehavioral Reviews|April 10, 2024
Why we need to pursue both universal and targeted prevention to reduce the incidence of affective and psychotic disorders: Systematic review and meta-analysisSebastien Brodeur, Dominic Oliver, Muhammad S Ahmed, et al.
Pageof 5